Empiric radiotherapy for lung cancer collaborative group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation

Abigail T. Berman, Salma K. Jabbour, Anil Vachani, Cliff Robinson, J. Isabelle Choi, Pranshu Mohindra, Ramesh Rengan, Jeffrey Bradley, Charles B. Simone

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The standard of care for managing early stage non-small cell lung cancer (NSCLC) is definitive surgical resection. Stereotactic body radiation therapy (SBRT) has become the standard treatment for patient who are medically inoperable, and it is increasingly being considered as an option in operable patients. With the growing use of screening thoracic CT scans for patients with a history of heavy smoking, as well as improved imaging capabilities, the discovery of small lung nodes has become a common dilemma. As a result, clinicians are increasingly faced with managing lung nodules in patients in whom diagnostic biopsy is not safe or feasible. Herein, we describe the scope of the problem, tools available for predicting the probability that a lung nodule is a malignancy, staging procedures, benefits of pathology-proven and empiric SBRT, considerations of safety based on location of the lesion of concern, and overall efficacy of SBRT.

Original languageEnglish (US)
Pages (from-to)5-14
Number of pages10
JournalTranslational Lung Cancer Research
Volume8
Issue number1
DOIs
StatePublished - Feb 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Radiotherapy
Guidelines
Lung
Standard of Care
Thorax
Smoking
Pathology
Biopsy
Safety
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Keywords

  • Empiric
  • Pathologic confirmation
  • Radiographic
  • Stereotactic body radiation therapy (SBRT)
  • Tissue diagnosis

Cite this

Berman, Abigail T. ; Jabbour, Salma K. ; Vachani, Anil ; Robinson, Cliff ; Isabelle Choi, J. ; Mohindra, Pranshu ; Rengan, Ramesh ; Bradley, Jeffrey ; Simone, Charles B. / Empiric radiotherapy for lung cancer collaborative group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. In: Translational Lung Cancer Research. 2018 ; Vol. 8, No. 1. pp. 5-14.
@article{fe0b375caf8e475a8b4e34dbb1b227fa,
title = "Empiric radiotherapy for lung cancer collaborative group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation",
abstract = "The standard of care for managing early stage non-small cell lung cancer (NSCLC) is definitive surgical resection. Stereotactic body radiation therapy (SBRT) has become the standard treatment for patient who are medically inoperable, and it is increasingly being considered as an option in operable patients. With the growing use of screening thoracic CT scans for patients with a history of heavy smoking, as well as improved imaging capabilities, the discovery of small lung nodes has become a common dilemma. As a result, clinicians are increasingly faced with managing lung nodules in patients in whom diagnostic biopsy is not safe or feasible. Herein, we describe the scope of the problem, tools available for predicting the probability that a lung nodule is a malignancy, staging procedures, benefits of pathology-proven and empiric SBRT, considerations of safety based on location of the lesion of concern, and overall efficacy of SBRT.",
keywords = "Empiric, Pathologic confirmation, Radiographic, Stereotactic body radiation therapy (SBRT), Tissue diagnosis",
author = "Berman, {Abigail T.} and Jabbour, {Salma K.} and Anil Vachani and Cliff Robinson and {Isabelle Choi}, J. and Pranshu Mohindra and Ramesh Rengan and Jeffrey Bradley and Simone, {Charles B.}",
year = "2018",
month = "2",
day = "1",
doi = "https://doi.org/10.21037/tlcr.2018.12.12",
language = "English (US)",
volume = "8",
pages = "5--14",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "1",

}

Empiric radiotherapy for lung cancer collaborative group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. / Berman, Abigail T.; Jabbour, Salma K.; Vachani, Anil; Robinson, Cliff; Isabelle Choi, J.; Mohindra, Pranshu; Rengan, Ramesh; Bradley, Jeffrey; Simone, Charles B.

In: Translational Lung Cancer Research, Vol. 8, No. 1, 01.02.2018, p. 5-14.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Empiric radiotherapy for lung cancer collaborative group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation

AU - Berman, Abigail T.

AU - Jabbour, Salma K.

AU - Vachani, Anil

AU - Robinson, Cliff

AU - Isabelle Choi, J.

AU - Mohindra, Pranshu

AU - Rengan, Ramesh

AU - Bradley, Jeffrey

AU - Simone, Charles B.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The standard of care for managing early stage non-small cell lung cancer (NSCLC) is definitive surgical resection. Stereotactic body radiation therapy (SBRT) has become the standard treatment for patient who are medically inoperable, and it is increasingly being considered as an option in operable patients. With the growing use of screening thoracic CT scans for patients with a history of heavy smoking, as well as improved imaging capabilities, the discovery of small lung nodes has become a common dilemma. As a result, clinicians are increasingly faced with managing lung nodules in patients in whom diagnostic biopsy is not safe or feasible. Herein, we describe the scope of the problem, tools available for predicting the probability that a lung nodule is a malignancy, staging procedures, benefits of pathology-proven and empiric SBRT, considerations of safety based on location of the lesion of concern, and overall efficacy of SBRT.

AB - The standard of care for managing early stage non-small cell lung cancer (NSCLC) is definitive surgical resection. Stereotactic body radiation therapy (SBRT) has become the standard treatment for patient who are medically inoperable, and it is increasingly being considered as an option in operable patients. With the growing use of screening thoracic CT scans for patients with a history of heavy smoking, as well as improved imaging capabilities, the discovery of small lung nodes has become a common dilemma. As a result, clinicians are increasingly faced with managing lung nodules in patients in whom diagnostic biopsy is not safe or feasible. Herein, we describe the scope of the problem, tools available for predicting the probability that a lung nodule is a malignancy, staging procedures, benefits of pathology-proven and empiric SBRT, considerations of safety based on location of the lesion of concern, and overall efficacy of SBRT.

KW - Empiric

KW - Pathologic confirmation

KW - Radiographic

KW - Stereotactic body radiation therapy (SBRT)

KW - Tissue diagnosis

UR - http://www.scopus.com/inward/record.url?scp=85060670531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060670531&partnerID=8YFLogxK

U2 - https://doi.org/10.21037/tlcr.2018.12.12

DO - https://doi.org/10.21037/tlcr.2018.12.12

M3 - Review article

VL - 8

SP - 5

EP - 14

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 1

ER -